Search

David Lee Tamang

from Wilmington, MA
Age ~46
Get Report
Also known as:
David L Tamang, Dave Tamang
Phone and address:
5 Meadowbrook Rd, Wilmington, MA 01887
Related to:
Angela M Catania, 45Paul CataniaMarianne Baez, 87
Connected to:
Dechen C TamangJharna Tamang, 32Mon Tamang, 41Sangita Tamang, 39Frank P Tamanini, 68John W Tamanini, 59Calvin A Tamano, 37Leonard TamaraLucia TamaraTina N Tamara, 55

David Tamang Phones & Addresses

  • 5 Meadowbrook Rd, Wilmington, MA 01887
  • Revere, MA
  • Watertown, MA
  • Somerville, MA
  • Malden, MA
  • Great Falls, MT
  • Reno, NV
  • Billings, MT
  • 140 Hillside Rd #3, Watertown, MA 02472

Education

Degree: Associate degree or higher

Publications

Us Patents

Pyrimidine Hydroxy Amide Compounds As Histone Deacetylase Inhibitors

View page
US Patent:
20160279128, Sep 29, 2016
Filed:
Jan 20, 2016
Appl. No.:
15/001847
Inventors:
- Boston MA, US
Ralph Mazitschek - Belmont MA, US
Simon Stewart Jones - Harvard MA, US
Min Yang - Newton MA, US
David Lee Tamang - Watertown MA, US
International Classification:
A61K 31/506
A61K 31/505
A61K 31/5377
Abstract:
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

Treatment Of Leukemia With Histone Deacetylase Inhibitors

View page
US Patent:
20160030458, Feb 4, 2016
Filed:
Jul 6, 2015
Appl. No.:
14/792046
Inventors:
- Boston MA, US
Chengyin Min - Brookline MA, US
Min Yang - Newton MA, US
David Lee Tamang - Watertown MA, US
International Classification:
A61K 31/706
A61K 31/496
A61K 31/5377
A61K 45/06
A61K 31/505
Abstract:
Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of leukemia in a subject in need thereof. Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of acute myelogenous leukemia in a subject in need thereof. Also provided herein are methods for treating leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor, as well as methods for treating acute myelogenous leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor.

Histone Deacetylase 6 (Hdac6) Biomarkers In Multiple Myeloma

View page
US Patent:
20150176076, Jun 25, 2015
Filed:
Dec 19, 2014
Appl. No.:
14/576313
Inventors:
- Boston MA, US
David Lee Tamang - Watertown MA, US
Simon Stewart Jones - Harvard MA, US
Assignee:
Acetylon Pharmaceuticals, Inc. - Boston MA
International Classification:
C12Q 1/68
A61K 31/505
Abstract:
The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

Pyrimidine Hydroxy Amide Compounds As Histone Deacetylase Inhibitors

View page
US Patent:
20150105384, Apr 16, 2015
Filed:
Oct 9, 2014
Appl. No.:
14/510711
Inventors:
Simon Stewart Jones - Harvard MA, US
Min Yang - Newton MA, US
David Lee Tamang - Watertown MA, US
Assignee:
Acetylon Pharmaceuticals, Inc. - Boston MA
International Classification:
C07D 417/12
C07D 401/14
C07D 239/42
C07D 401/12
US Classification:
5142352, 544332, 514275, 544143
Abstract:
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

Combinations Of Histone Deacetylase Inhibitors And Either Her2 Inhibitors Or Pi3K Inhibitors

View page
US Patent:
20150099744, Apr 9, 2015
Filed:
Oct 6, 2014
Appl. No.:
14/506889
Inventors:
David Lee Tamang - Watertown MA, US
Min Yang - Newton MA, US
Simon S. Jones - Boston MA, US
Assignee:
Acetylon Pharmaceuticals, Inc. - Boston MA
International Classification:
C07D 239/42
A61K 31/517
A61K 31/5377
A61K 31/505
US Classification:
5142342, 514275, 51426624
Abstract:
The invention relates to combinations comprising an HDAC inhibitor and a Her2 inhibitor for the treatrent of breast cancer in a subject in need thereof. The invention also relates to combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of breast cancer in a subject in need thereof. Also provided herein are methods for treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations. Further provided are methods for inhibiting migration and/or invasion of a breast cancer cell in a subject by administering to the subject a HDAC6 specific inhibitor.
Control profile
David Lee Tamang from Wilmington, MA, age ~46 Get Report